Cleo DiagnosticsASX:COV -2.00%17 OCF Yield % is -3.85 as of Jul. 02, 2026. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 68.65% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Cleo Diagnostics's OCF Yield % or its related term are showing as below:
ASX:COV'
s OCF Yield % Range Over the Past 10 Years
Min: -3.85 Med: 0 Max: -3.85
Current: -3.85
During the past 3 years, the highest OCF Yield % of Cleo Diagnostics was -3.85%. The lowest was -3.85%. And the median was %.
ASX:COV's OCF Yield % is ranked worse than 68.65% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.71
vs ASX:COV: -3.85
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cleo Diagnostics OCF Yield % Related Terms
Cleo Diagnostics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cleo Diagnostics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cleo Diagnostics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleo Diagnostics (ASX:COV) has a OCF Yield % of -3.85 as of Jul. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #587 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 68.7%.
Is Cleo Diagnostics' OCF Yield % too high?
Cleo Diagnostics' current OCF Yield % is -3.85. Based on the distribution chart, Cleo Diagnostics ranks #587 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #587 out of 855 companies for OCF Yield %. This places Cleo Diagnostics in the lower half of its industry. The industry median OCF Yield % is 1.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.71, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current OCF Yield % is -3.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current OCF Yield % of -3.85. The current OCF Yield % is -3.85. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current OCF Yield % is -3.85 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score
Get the complete analysis for ASX:COV
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 